Live News • Aug 03
enGene Therapeutics Interim Trial Results Trigger Analyst Downgrades and Steep Price Decline enGene Therapeutics reported updated interim data from its Phase 2 LEGEND trial, with a 54% complete response rate at any time and a 25% complete response rate at 12 months, which prompted analyst downgrades and a sharp reassessment of its lead program.
The market reaction has been severe, with enGene Therapeutics’ stock now at $1.79 and the share price down 75.3% over the past 90 days.
Management has described the LEGEND data as preliminary and plans a further update in the second half of 2026, which leaves a long information gap for the market to absorb.
The key issue for investors is how much confidence to place in a program where interim durability data has already led to a major reset in expectations and where the next data catalyst is still some distance away. Live News • Jul 20
enGene Therapeutics 12-Month Trial Data Spurs Analyst Downgrades and Sharp Valuation Drop enGene Therapeutics released updated interim data from its Phase 2 LEGEND trial, reporting a 54% complete response rate at any time and a 25% complete response rate at 12 months. The results prompted analyst downgrades and a reassessment of the trial’s perceived strength.
The company’s CEO described the LEGEND results as preliminary and indicated that further updates are expected in the second half of 2026, noting that the current dataset may evolve as longer-term outcomes are collected.
enGene Therapeutics shares trade at $1.82, with the stock down about 79.4% year to date, reflecting the valuation’s sensitivity to changes in expectations around this trial.
The key risk is that enGene Therapeutics appears heavily reliant on LEGEND, so any further weakness or uncertainty in long-term response data could continue to affect both sentiment and access to capital. Announcement • Jul 16
Engene Therapeutics Inc. Announces Board Changes enGene Therapeutics Inc. announced that Michael Heffernan, who has served on our Board since July 2025, will assume the role of Chairman. Dr. Richard Glickman to step down as chairman. Dr. Richard Glickman has served as enGene’s Chairman for over 14 years. His expertise was instrumental in supporting the Company’s scientific and medical leadership in the development of its unique Dually Derivatized Oligochitosan® (DDX) platform, enabling non-viral gene transfection. His experience in company formation, capital raising and capital markets was also critical in guiding enGene’s transition from a seed-stage venture to a publicly listed company. Dr. Glickman continues to serve on the boards of several biotechnology companies. Michael Heffernan is a seasoned biopharmaceutical executive and entrepreneur with over 30 years of experience in the industry. He was the Founder of Collegium Pharmaceutical and has previously served as its President and Chief Executive Officer, as well as Chairman of the Board. Mr. Heffernan has built and led multiple companies through numerous financings and successful exits. He has also held leadership positions at Onset Dermatologics, Clinical Studies Ltd., and Eli Lilly and Company. Currently, Mr. Heffernan serves as Chairman of the Board at NMD Pharma, Avalo Therapeutics and AAVantgarde Bio, and is a board member at Biohaven, Trevi Therapeutics, and K36 Therapeutics. He holds a Bachelor of Science in Pharmacy from the University of Connecticut and is a registered pharmacist. 
